Effect on disease activity of ofatumumab in the treatment of glial fibrillary acidic protein astrocytopathy and 18F-DPA714 PET/MRI imaging assessment

IF 2.5 4区医学 Q3 IMMUNOLOGY

Journal of neuroimmunology Pub Date : 2026-04-01 Epub Date: 2026-01-12 DOI:10.1016/j.jneuroim.2026.578862

Yingbo Han , Xiaoyu Chen , Qinming Zhou , Ruifen Duan , Mengmeng Zhang , Sheng Chen , Huanyu Meng

{"title":"Effect on disease activity of ofatumumab in the treatment of glial fibrillary acidic protein astrocytopathy and 18F-DPA714 PET/MRI imaging assessment","authors":"Yingbo Han , Xiaoyu Chen , Qinming Zhou , Ruifen Duan , Mengmeng Zhang , Sheng Chen , Huanyu Meng","doi":"10.1016/j.jneuroim.2026.578862","DOIUrl":null,"url":null,"abstract":"<div><div>A 49-year-old male with Glial Fibrillary Acidic Protein Astrocytopathy (GFAP-A) presented with progressive cognitive decline, visual hallucinations, and bowel/bladder incontinence. Brain MRI revealed extensive white matter hyperintensities on T2-FLAIR sequences. After suboptimal response to first-line treatments including corticosteroids and intravenous immunoglobulin (IVIg), the patient was initiated on Ofatumumab (OFA) therapy. Treatment response was systematically monitored through validated clinical assessment tools (MMSE, MoCA, mRS, and CASE) and advanced neuroimaging, including conventional MRI and <sup>18</sup>F-DPA714 PET. Following OFA treatment, the patient demonstrated marked clinical improvement and radiological resolution. Notably, <sup>18</sup>F-DPA714 PET imaging captured dynamic changes in neuroinflammation and revealed distinct patterns not apparent on conventional MRI. This case demonstrates the potential effect on disease activity and safety of OFA in GFAP-A treatment while highlighting the value of <sup>18</sup>F-DPA714 PET as an innovative tool for monitoring neuroinflammation and therapeutic response. To our knowledge, this represents the first comprehensive multimodal assessment using <sup>18</sup>F-DPA714 PET/MRI in a GFAP-A patient treated with ofatumumab.</div></div>","PeriodicalId":16671,"journal":{"name":"Journal of neuroimmunology","volume":"413 ","pages":"Article 578862"},"PeriodicalIF":2.5000,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of neuroimmunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S016557282600010X","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/12 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

A 49-year-old male with Glial Fibrillary Acidic Protein Astrocytopathy (GFAP-A) presented with progressive cognitive decline, visual hallucinations, and bowel/bladder incontinence. Brain MRI revealed extensive white matter hyperintensities on T2-FLAIR sequences. After suboptimal response to first-line treatments including corticosteroids and intravenous immunoglobulin (IVIg), the patient was initiated on Ofatumumab (OFA) therapy. Treatment response was systematically monitored through validated clinical assessment tools (MMSE, MoCA, mRS, and CASE) and advanced neuroimaging, including conventional MRI and ¹⁸F-DPA714 PET. Following OFA treatment, the patient demonstrated marked clinical improvement and radiological resolution. Notably, ¹⁸F-DPA714 PET imaging captured dynamic changes in neuroinflammation and revealed distinct patterns not apparent on conventional MRI. This case demonstrates the potential effect on disease activity and safety of OFA in GFAP-A treatment while highlighting the value of ¹⁸F-DPA714 PET as an innovative tool for monitoring neuroinflammation and therapeutic response. To our knowledge, this represents the first comprehensive multimodal assessment using ¹⁸F-DPA714 PET/MRI in a GFAP-A patient treated with ofatumumab.

查看原文本刊更多论文

ofatumumab治疗胶质纤维酸性蛋白星形细胞病对疾病活动性的影响及18F-DPA714 PET/MRI成像评估

一位49岁男性胶质纤维酸性蛋白星形细胞病（gmap -A）表现为进行性认知能力下降，视觉幻觉和肠/膀胱失禁。脑MRI在T2-FLAIR序列上显示广泛的白质高信号。在对包括皮质类固醇和静脉注射免疫球蛋白（IVIg）在内的一线治疗反应不佳后，患者开始接受Ofatumumab （OFA）治疗。通过有效的临床评估工具（MMSE、MoCA、mRS和CASE）和先进的神经影像学（包括常规MRI和18F-DPA714 PET）系统监测治疗反应。经OFA治疗后，患者表现出明显的临床改善和放射学缓解。值得注意的是，18F-DPA714 PET成像捕获了神经炎症的动态变化，并显示了传统MRI上不明显的独特模式。该病例证明了OFA在gap - a治疗中对疾病活动性和安全性的潜在影响，同时强调了18F-DPA714 PET作为监测神经炎症和治疗反应的创新工具的价值。据我们所知，这是首次在接受ofatumumab治疗的gap - a患者中使用18F-DPA714 PET/MRI进行全面的多模式评估。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of neuroimmunology 医学-免疫学

CiteScore

6.10

自引率

3.00%

发文量

154

审稿时长

37 days

期刊介绍： The Journal of Neuroimmunology affords a forum for the publication of works applying immunologic methodology to the furtherance of the neurological sciences. Studies on all branches of the neurosciences, particularly fundamental and applied neurobiology, neurology, neuropathology, neurochemistry, neurovirology, neuroendocrinology, neuromuscular research, neuropharmacology and psychology, which involve either immunologic methodology (e.g. immunocytochemistry) or fundamental immunology (e.g. antibody and lymphocyte assays), are considered for publication.